■ Published papers
|
Original article
|
|
1.
|
Wilding, B., Woelflingseder, L., Baum, A., Chylinski, K., Vainorius, G., Gibson, N., Waizenegger, I. C., Gerlach, D., Augsten, M., Spreitzer, F., Shirai, Y., Ikegami, M., Tilandyová, S., Scharn, D., Pearson, M. A., Popow, J., Obenauf, A. C., Yamamoto, N., Kondo, S., Opdam, F. L., Bruining, A., Kohsaka, S., Kraut, N., Heymach, J. V., Solca, F., Neumüller, R. A.：
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Cancer Discov
15
：119-138
, 2025.1
DOI:10.1158/2159-8290.CD-24-0306
|
|
2.
|
Baba Shogo, Kawasaki Tadatoshi, Hirano Satoshi, Nakamura Toru, Asano Toshimichi, Okazaki Ryo, Yoshida Koji, Kawase Tomoya, Kurahara Hiroshi, Oi Hideyuki, Yokoyama Masaya, Kita Junji, Imura Johji, Kinoshita Kazuya, Kondo Shunsuke, Okada Mao, Satake Tomoyuki, Igawa Yukiko Shimoda, Yoshida Tatsuya, Yamaguchi Hiroki, Ando Yoriko, Mizunuma Mika, Ichikawa Yuki, Hida Kyoko, Nishihara Hiroshi, Kato Yasutaka：
A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study.
EClinicalMedicine
78
：102936
, 2024.12
DOI:10.1016/j.eclinm.2024.102936
|
|
3.
|
Hagiwara Yuya, Hijioka Susumu, Nagashio Yoshikuni, Maruki Yuta, Ohba Akihiro, Kawasaki Yuki, Takeshita Kotaro, Takasaki Tetsuro, Agarie Daiki, Hara Hidenobu, Yagi Shin, Fukuda Soma, Kuwada Masaru, Yamashige Daiki, Okamoto Kohei, Chatto Mark, Kondo Shunsuke, Morizane Chigusa, Ueno Hideki, Endo Masato, Sugawara Shunsuke, Sone Miyuki, Saito Yutaka, Tsuchiya Kiichiro, Okusaka Takuji：
Efficacy of endoscopic ultrasound-guided gastroenterostomy using self-expandable metallic stent for afferent loop syndrome: A single-center retrospective study.
Journal of gastroenterology and hepatology
39
(10)
：2136-2142
, 2024.10
DOI:10.1111/jgh.16649
|
|
4.
|
Yamamoto Noboru, Koyama Takafumi, Sato Jun, Yoshida Tatsuya, Sudo Kazuki, Iwasa Satoru, Kondo Shunsuke, Yonemori Kan, Kawasaki Atsuko, Satake Kyoko, Shibata Shoyo, Shimizu Toshio：
Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Cancer chemotherapy and pharmacology
94
(3)
：491
, 2024.9
DOI:10.1007/s00280-024-04645-9
|
|
5.
|
Wilding Birgit, Woelflingseder Lydia, Baum Anke, Chylinski Krzysztof, Vainorius Gintautas, Gibson Neil, Waizenegger Irene C, Gerlach Daniel, Augsten Martin, Spreitzer Fiona, Shirai Yukina, Ikegami Masachika, Tilandyova Sylvia, Scharn Dirk, Pearson Mark A, Popow Johannes, Obenauf Anna C, Yamamoto Noboru, Kondo Shunsuke, Opdam Frans L, Bruining Annemarie, Kohsaka Shinji, Kraut Norbert, Heymach John V, Solca Flavio, Neumuller Ralph A：
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers.
Cancer discovery
：119
, 2024.9
DOI:10.1158/2159-8290.CD-24-0306
|
|
6.
|
Koyama Takafumi, Yonemori Kan, Shimizu Toshio, Sato Jun, Kondo Shunsuke, Sudo Kazuki, Yoshida Tatsuya, Katsuya Yuki, Imaizumi Tatsuki, Enomoto Masashi, Seki Ryoko, Yamamoto Noboru：
Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors.
Cancer research communications
4
(9)
：2349-2358
, 2024.9
DOI:10.1158/2767-9764.CRC-24-0185
|
|
7.
|
Yamamoto Noboru, Kuboki Yasutoshi, Harano Kenichi, Koyama Takafumi, Kondo Shunsuke, Hagiwara Akiko, Suzuki Noriko, Fujikawa Ei, Toyoizumi Kiichiro, Mukai Mayumi, Doi Toshihiko：
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.
Investigational new drugs
42
(4)
：376-385
, 2024.8
DOI:10.1007/s10637-024-01433-3
|
|
8.
|
Okamoto Kohei, Hijioka Susumu, Nagashio Yoshikuni, Okada Mao, Ohba Akihiro, Maruki Yuta, Kondo Shunsuke, Morizane Chigusa, Ueno Hideki, Okusaka Takuji：
Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments.
Japanese journal of clinical oncology
54
(8)
：887-894
, 2024.8
DOI:10.1093/jjco/hyae060
|
|
9.
|
Kuboki Yasutoshi, Koyama Takafumi, Matsubara Nobuaki, Naito Yoichi, Kondo Shunsuke, Harano Kenichi, Yonemori Kan, Yoh Kiyotaka, Gu Yuan, Mita Tetsuya, Chen Xuejun, Ueda Eiji, Yamamoto Noboru, Doi Toshihiko, Shimizu Toshio：
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Cancer medicine
13
(8)
：e6980
, 2024.4
DOI:10.1002/cam4.6980
|
|
10.
|
Kawamoto Yasuyuki, Morizane Chigusa, Komatsu Yoshito, Kondo Shunsuke, Ueno Makoto, Kobayashi Satoshi, Furukawa Masayuki, Lee Lingaku, Satoh Taroh, Sakai Daisuke, Ikeda Masafumi, Imaoka Hiroshi, Miura Arisa, Hatanaka Yutaka, Yokota Isao, Nakamura Yoshiaki, Yoshino Takayuki：
Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
Future oncology (London, England)
：1-7
, 2024.4
DOI:10.2217/fon-2023-0348
|
|
11.
|
Kondo Shunsuke, Katsuya Yuki, Yonemori Kan, Komuro Keiko, Sugeno Masatoshi, Kawata Toshio, Ghiorghiu Dana, Meulendijks Didier, Yamamoto Noboru：
Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.
Cancer treatment and research communications
39
：100809
, 2024
DOI:10.1016/j.ctarc.2024.100809
|
|
Display 5 items
|
|
Display all(11)
|
|
To the top
|
|
